Medtronic (MDT) Stock Dips While Market Gains: Key Facts

Medtronic (MDT) closed the most recent trading day at $94.21, moving -1.76% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.58%. At the same time, the Dow added 0.31%, and the tech-heavy Nasdaq gained 0.89%. Shares of the medical device company have appreciated by 0.17% over the course of the past month, underperforming the Medical sector's gain of 3.7%, and outperforming the S&P 500's gain of 0.16%.The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on November 18, 2025. The company's earnings per share (EPS) are projected to be $1.31, reflecting a 3.97% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $8.86 billion, indicating a 5.44% upward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.62 per share and a revenue of $35.83 billion, representing changes of +2.37% and +6.82%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Right now, Medtronic possesses a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Medtronic has a Forward P/E ratio of 17.08 right now. For comparison, its industry has an average Forward P/E of 18.46, which means Medtronic is trading at a discount to the group. Meanwhile, MDT's PEG ratio is currently 2.53. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 2.32 at the close of the market yesterday. The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 149, which puts it in the bottom 40% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks